Tibet Weixinkang Medicine Co., Ltd.
603676.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.99B
Close$
$14.88
64.6% upside
Current Fair Value
64.6% upsideUndervalued by 64.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.99 Billion |
|---|---|
| Enterprise Value | $3.73 Billion |
| Dividend Yield | $0.33 (3.56%) |
| Earnings per Share | $0.54 |
| Beta | -0.04 |
| Outstanding Shares | 432,334,800 |
Return
| Return on Equity | 12.53% |
|---|---|
| Return on Assets | 9.82% |
| Return on Invested Capital | 14.89% |
Valuation & Multiples
| P/E Ratio | 20.45 |
|---|---|
| PEG | -84.95 |
| Price to Sales | 4.52 |
| Price to Book Ratio | 3.01 |
| Enterprise Value to Revenue | 3.29 |
| Enterprise Value to EBIT | 15.83 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tibet Weixinkang Medicine Co., Ltd.
763 employees
CEO: Yong Zhang Tibet Weixinkang Medicine Co., Ltd., a pharmaceutical enterprise headquartered in Lhasa, China, is dedicated to the entire lifecycle of medicinal products within the country, encompassing their research and development, manufacturing, an...